* Patients can try NITYR for three weeks for free as long as their doctor prescribes it. Subject to terms and conditions, eligibility criteria, and to other federal and state law.

See offer

* For eligible commercially insured patients. Doctor’s prescription required. Subject to terms and conditions and eligibility criteria. Program not available for government-insured patients and subject to other federal and state law.

See offer
This site is intended for US healthcare professionals NITYR Back to top
Safety InformationPrescribing Information


Tyrosinemia Connections: A Live Community Event

We are extremely excited to present to you a new monthly educational online community meeting series titled…

Cycle Pharmaceuticals’ Nityr® Supply Chain Update

At Cycle Pharmaceuticals, the health and safety of patients with tyrosinemia type 1 (HT-1) is our top priority. As the…

Sign up for updates

Please click the button below and fill out the form to sign up to updates from our newsletter.

Sign up

Meet Alina and learn about her journey with NITYR (nitisinone) Tablets

Alina has taken NITYR (nitisinone) tablets since she was born. Hear about their story with NITYR.

Cycle Pharmaceuticals and NITYR (nitisinone) Tablets is extremely pleased to…

Following the launch of NITYR (nitisinone) tablets since August 2017, we are delighted to announce that 50 patients are…

24 Patients Now Receiving NITYR in the US

Following the launch of NITYR (nitisinone) tablets in the US last year, we are delighted to announce that 24 patients…

Boston, US. Office Opens

We are pleased to announce that we have opened new offices in Boston, Mass., US. The new offices will act as a base for…

Cycle Pharmaceuticals Receives Approval for Updated Infant Administration for NITYR (nitisinone) Tablets for HT-1 in U.S.

Cycle Pharmaceuticals (Cycle) is pleased to announce that the U.S. Food and Drug Administration (FDA) has approved a…


Sign up for updates